Literature DB >> 15166277

Chlamydia trachomatis serovar E isolates from patients with different clinical manifestations have similar courses of infection in a murine model: host factors as major determinants of C trachomatis mediated pathogenesis.

J M Lyons1, J I Ito, S A Morré.   

Abstract

BACKGROUND: Some investigators have proposed an association between certain Chlamydia trachomatis serovars and the clinical course of infection in humans. A recent study of over 1100 patients with culture confirmed and serotyped C trachomatis urogenital infection detected no such association. AIMS: To corroborate these results using a murine model of female genital tract infection.
METHODS: Various parameters of infection were assessed in mice intravaginally infected with human genital isolates of C trachomatis serovar E from four cases with either a clear symptomatic or asymptomatic clinical course in both the patient and their partner.
RESULTS: No differences were seen among the strains in the incidence or duration of infection, polymorphonuclear granulocyte responses, or upper genital tract progression.
CONCLUSIONS: An investigation to determine the correlation between the clinical manifestations of different isolates of C trachomatis serovar E in humans and certain parameters of microbial pathogenesis in a mouse model failed to reveal an association between the measured parameters and the tendency of serovar E to produce symptomatic versus asymptomatic infections in humans. These findings suggest that differences in the clinical course of infection in humans seen with these strains may be more related to host factors than to genetic variation among strains.

Entities:  

Mesh:

Year:  2004        PMID: 15166277      PMCID: PMC1770319          DOI: 10.1136/jcp.2003.013086

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  The role that the functional Asp299Gly polymorphism in the toll-like receptor-4 gene plays in susceptibility to Chlamydia trachomatis-associated tubal infertility.

Authors:  Servaas A Morré; Laura S Murillo; Cathrien A Bruggeman; A Salvador Peña
Journal:  J Infect Dis       Date:  2003-01-15       Impact factor: 5.226

2.  Human leukocyte antigen class II DQ alleles associated with Chlamydia trachomatis tubal infertility.

Authors:  C R Cohen; S S Sinei; E A Bukusi; J J Bwayo; K K Holmes; R C Brunham
Journal:  Obstet Gynecol       Date:  2000-01       Impact factor: 7.661

3.  Variation in virulence among oculogenital serovars of Chlamydia trachomatis in experimental genital tract infection.

Authors:  J I Ito; J M Lyons; L P Airo-Brown
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

4.  RNA amplification by nucleic acid sequence-based amplification with an internal standard enables reliable detection of Chlamydia trachomatis in cervical scrapings and urine samples.

Authors:  S A Morré; P Sillekens; M V Jacobs; P van Aarle; S de Blok; B van Gemen; J M Walboomers; C J Meijer; A J van den Brule
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

5.  Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates.

Authors:  Harlan D Caldwell; Heidi Wood; Debbie Crane; Robin Bailey; Robert B Jones; David Mabey; Ian Maclean; Zeena Mohammed; Rosanna Peeling; Christine Roshick; Julius Schachter; Anthony W Solomon; Walter E Stamm; Robert J Suchland; Lacey Taylor; Sheila K West; Tom C Quinn; Robert J Belland; Grant McClarty
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

6.  Establishment of genital tract infection in the CF-1 mouse by intravaginal inoculation of a human oculogenital isolate of Chlamydia trachomatis.

Authors:  J I Ito; H R Harrison; E R Alexander; L J Billings
Journal:  J Infect Dis       Date:  1984-10       Impact factor: 5.226

Review 7.  The relationship of serovar to clinical manifestations of urogenital Chlamydia trachomatis infection.

Authors:  William M Geisler; Robert J Suchland; William L H Whittington; Walter E Stamm
Journal:  Sex Transm Dis       Date:  2003-02       Impact factor: 2.830

8.  HLA DQ alleles and interleukin-10 polymorphism associated with Chlamydia trachomatis-related tubal factor infertility: a case-control study.

Authors:  A H Kinnunen; H-M Surcel; M Lehtinen; J Karhukorpi; A Tiitinen; M Halttunen; A Bloigu; R P Morrison; R Karttunen; J Paavonen
Journal:  Hum Reprod       Date:  2002-08       Impact factor: 6.918

9.  Genotyping of Chlamydia trachomatis serovars derived from heterosexual partners and a detailed genomic analysis of serovar F.

Authors:  J Lan; C J Meijer; A R van den Hoek; J M Ossewaarde; J M Walboomers; A J van den Brule
Journal:  Genitourin Med       Date:  1995-10
  9 in total
  4 in total

1.  Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection.

Authors:  Daisy Vanrompay; Thi Q T Hoang; Liselotte De Vos; Kristel Verminnen; Taher Harkinezhad; Koen Chiers; Servaas A Morré; Eric Cox
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Vertical transmission of Chlamydia trachomatis in Chongqing China.

Authors:  Jialin Yu; Shixiao Wu; Fang Li; Linyan Hu
Journal:  Curr Microbiol       Date:  2009-01-03       Impact factor: 2.188

3.  The CD14 functional gene polymorphism -260 C>T is not involved in either the susceptibility to Chlamydia trachomatis infection or the development of tubal pathology.

Authors:  Sander Ouburg; Joke Spaargaren; Janneke E den Hartog; Jolande A Land; Johan S A Fennema; Jolein Pleijster; A Salvador Peña; Servaas A Morré
Journal:  BMC Infect Dis       Date:  2005-12-20       Impact factor: 3.090

4.  The vaginal microbiome is stable in prepubertal and sexually mature Ellegaard Göttingen Minipigs throughout an estrous cycle.

Authors:  Emma Lorenzen; Egle Kudirkiene; Nicole Gutman; Anette Blak Grossi; Jørgen Steen Agerholm; Karin Erneholm; Christina Skytte; Marlene Danner Dalgaard; Anders Miki Bojesen
Journal:  Vet Res       Date:  2015-10-28       Impact factor: 3.683

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.